NuVasive

In a report published by Piper Jaffray, NuVasive (NASDAQ: NUVA) Overweight rating is reiterated. Piper Jaffray said that it travelled with management for a series of investor meetings yesterday and came away with some fresh insights on the company and its prospects. “While a number of questions...

In a report published by J.P. Morgan, NuVasive's (NASDAQ: NUVA) 2011 estimates are to be adjusted following its 4Q10 results. J.P. Morgan said that, for 2011 it now expects adjusted EPS of $1.10 (-25.5%) on total revenues of $536.2M (+12.1%). “Both of these estimates lie at the high end of...

NuVasive, Inc. (NASDAQ: NUVA) reported full 4Q results Wednesday after the close that were roughly in line with the company's earlier preannouncement, “with revenues of $129.3M (+20.9%) coming in $6.0M above our estimate,” J.P. Morgan reports. “On the bottom line, adjusted EPS of $0.46 was $0.04...

Piper Jaffray has raised the price target on NuVasive (NASDAQ: NUVA) from $38 to $39 and maintains its Overweight rating.

Despite near-term challenges and uncertainty in the spine market, Jefferies said that it remains positive on the NuVasive, Inc. (NASDAQ: NUVA) story and believe the stock should reward long-term investors. “We rate the shares Buy,” Jefferies writes. “NUVA released preliminary earnings this evening...

Monday after the close, NuVasive, Inc. (NASDAQ: NUVA) announced preliminary 4Q results and once again amended its outlook for 2011 ahead of its upcoming presentation at the J.P.Morgan Healthcare conference (Tuesday at 11:30 a.m. EST). “Full year 2010 revenues are now expected to come in at $478M...

Jefferies & Company has lowered the price target on NuVasive, Inc. (NYSE: NUVA) from $36 to $34 and maintains its Buy rating.

JP Morgan has upgraded NuVasive, Inc. (NASDAQ: NUVA) from Underweight to Neutral and has raised the price target from $25 to $29.

J.P. Morgan is lowering its rating on NuVasive, Inc. (NASDAQ: NUVA) to UW following the company's second downward revision to 2010 guidance in as many months. J.P. Morgan said that the Spine market is under attack, Nuvasive is under attack, and the headwinds are, to say the least, increasing. “We'...

PiperJaffray analysts Matt Miksic and Roshni Sacks reiterated their Overweight rating for shares of NuVasive, Inc. (Nasdaq: NUVA) and lowered their price target from $55 to $47. The analysts noted that, "the company's reclassification of certain operating expenses, unveiled a level of gross profit...